Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.

One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted less in urine.

The lipid solubility of a drug also affects its renal clearance. Lipophilic drugs have a high affinity for fatty tissues and can be passively reabsorbed in the renal tubules, decreasing urinary excretion. This means an inverse relationship exists between lipid solubility and urinary excretion.

Stereoselectivity, particularly in protein-bound drugs, can also impact filtration rates for enantiomers (mirror-image molecules with identical chemical compositions but different spatial arrangements). The kidneys may exhibit different filtration rates for these enantiomers, leading to variations in their renal clearance.

Active tubular secretion and reabsorption processes also influence renal clearance. This is observed in drugs like chloroquine and glucose. Chloroquine is secreted into the renal tubules, while glucose is reabsorbed. These active transport mechanisms contribute to the overall renal clearance of these drugs.

Plasma drug concentration is another critical factor affecting renal clearance. Non-protein-bound drugs eliminated primarily by glomerular filtration show a linear relationship between the rate of excretion and plasma drug concentration. In other words, as the plasma drug concentration increases, the excretion rate increases proportionally. Their excretion depends on whether their concentration exceeds the maximum reabsorption capacity for actively reabsorbed drugs. Once this threshold is surpassed, these drugs are excreted into the urine. Similarly, actively secreted drugs exhibit increasing excretion rates until a point of saturation is reached, where further increases in drug concentration do not result in higher excretion rates.